Related Experiment Video
Updated: Mar 3, 2026
09:06
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
459
miRNAs: micro-managers of anticancer combination therapies
Judy R van Beijnum1, Elisa Giovannetti2, Dennis Poel1
1Angiogenesis Laboratory, Department of Medical Oncology, VUMC - Cancer Center Amsterdam, VU University Medical Center (VUmc), Amsterdam, The Netherlands.
Angiogenesis
|May 6, 2017
Summary
MicroRNAs (miRNAs) show promise in cancer therapy by targeting angiogenesis. Combining miRNA-based treatments with other therapies may improve outcomes in oncology.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Angiogenesis is crucial for cancer growth and a therapeutic target.
- Previous anti-angiogenic therapies have shown limitations.
- Combination therapies are increasingly important in cancer treatment.
Purpose of the Study:
- To review the role of microRNAs (miRNAs) in tumor angiogenesis.
- To explore the therapeutic potential of miRNAs in anti-angiogenesis cancer treatment.
- To discuss miRNA mimics and antagonists in clinical development.
Main Methods:
- Literature review of angiogenesis and miRNA research.
- Analysis of miRNA functions as tumor suppressors, oncogenes (oncomiRs), and angiomiRs.
- Examination of current clinical trials involving miRNA therapeutics.
Main Results:
- miRNAs play significant roles in tumor development, progression, and angiogenesis.
- miRNA mimics and antagonists are emerging as viable therapeutic tools.
- miRNAs offer potential for combination therapies in anti-angiogenesis treatment.
Conclusions:
- miRNAs are promising targets and therapeutics for anti-angiogenesis cancer strategies.
- Combination approaches involving miRNAs could overcome limitations of single-agent therapies.
- Further research and clinical development of miRNA-based treatments are warranted.
Related Concept Videos
01:22MicroRNAs
4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
01:22MicroRNAs
24.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K